Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 67
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodyn… |
RO7268489 | SEP | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | Australia, Brazil, France, Germany, Hungary, Italy, N… | 2026-03-10 → 2030-05-30 | Ouvrir |
| NCT04855617 Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclero… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Elliot Lewis Center for Multiple Scle… | 2020-10-26 → 2022-10-01 | Ouvrir |
| NCT02637856 A Study of Ocrelizumab in Participants With Relapsing Remitting Multipl… |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Canada · Advanced Neurology of Colorad… | 2016-02-11 → 2019-05-03 | Ouvrir |
| NCT07472413 Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Pr… |
Cetirizine | SEP | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | University of Miami | United States · UHealth Boca Raton, Boca Raton, Unite… | 2026-11-01 → 2028-07-01 | Ouvrir |
| NCT03562975 Upper Extremity Function in Multiple Sclerosis Patients With Advanced D… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Carol and Frank Morsani Center for Ad… | 2018-07-23 → 2023-01-11 | Ouvrir |
| NCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocr… |
CYB704 | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sandoz | United States, Bosnia and Herzegovina, Bulgaria, Croa… | 2025-06-10 → 2027-05 | Ouvrir |
| NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety … |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia… | 2018-07-12 → 2025-07-17 | Ouvrir |
| NCT03477500 Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Al… |
Cyclophosphamide and ATG | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Haukeland University Hospital | Denmark, Netherlands, Norway, Sweden · Akademiska sju… | 2018-03-21 → 2028-03-21 | Ouvrir |
| NCT07827586 SONATA-MS — Non-interventional Study of Subcutaneous Ocrelizumab in Per… |
Ocrelizumab | SEP | À vérifier | NOT_YET_RECRUITING | En attente / non publié | Hoffmann-La Roche | Non communiqué | 2026-09-30 → 2029-05-31 | Ouvrir |
| NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib… |
Fenebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Australia, Austria, Brazil,… | 2020-10-26 → 2027-07-21 | Ouvrir |
| NCT04377555 Prospective Study to Assess Disease Activity and Biomarkers in Minority… |
Ocrelizumab | SEP | Phase 4 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Kenya, Puerto Rico · Atlanta Neuroscie… | 2020-07-30 → 2025-11-11 | Ouvrir |
| NCT07779460 A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevu… |
A Study Comparing Effectiveness o… | SEP | À vérifier | RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States · Novartis, East Hanover, United States | 2026-04-08 → 2026-12-31 | Ouvrir |
| NCT04688788 DanNORMS — Non-inferiority Study of Ocrelizumab and Rituximab in Active… |
Rituximab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | Denmark · Danish Multiple Sclerosis Center, Rigshospi… | 2021-04-28 → 2029-06-10 | Ouvrir |
| NCT04075266 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remit… |
Ocrelizumab | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Italy, Poland · AOU Policlinico V. Ema… | 2020-01-09 → 2032-04-26 | Ouvrir |
| NCT07609719 OSSIA — A Study of Ocrelizumab Administered Subcutaneously in Participa… |
OCR SC | SEP | Phase 4 | RECRUITING | En attente / non publié | Genentech, Inc. | United States, Puerto Rico · Atlanta Neuroscience Ins… | 2026-09-02 → 2029-02-28 | Ouvrir |
| NCT07483450 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmac… |
Ocrelizumab | SEP | Phase 4 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | China · 1st Affiliated Hospital of Shanxi Medical Uni… | 2025-07-04 → 2028-12-31 | Ouvrir |
| NCT03972306 A Study To Investigate The Pharmacokinetics, Safety, And Tolerability O… |
Ocrelizumab | SEP | Phase 1 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Cleveland Clinic Mellen Center, Cleve… | 2019-08-12 → 2025-06-03 | Ouvrir |
| NCT04261790 Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple… |
Ocrelizumab | SEP | Phase 4 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Johns Hopkins University, Baltimore, … | 2020-08-01 → 2024-11-01 | Ouvrir |
| NCT07181811 ML45855 — Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on… |
ML45855 — Assessing the Effects o… | SEP | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Anza Memon | United States · John D. Dingell VA Medical Center, De… | 2025-09-30 → 2028-06-01 | Ouvrir |
| NCT02861014 A Study of Ocrelizumab in Participants With Relapsing Remitting Multipl… |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | Australia, Belgium, Czechia, Denmark, Estonia, Finlan… | 2016-09-09 → 2020-12-15 | Ouvrir |
| NCT04902690 The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Exp… |
The Possible Neuroprotective Effe… | SEP | À vérifier | UNKNOWN | En attente / non publié | IRCCS National Neurological Insti… | Non communiqué | 2021-05-31 → 2024-07-31 | Ouvrir |
| NCT04863586 COVID-19 and Multiple Sclerosis Disease Modifying Therapies |
COVID-19 and Multiple Sclerosis D… | SEP | À vérifier | UNKNOWN | En attente / non publié | Nottingham University Hospitals N… | United Kingdom · Nottingham University Hospitals NHS … | 2021-04-01 → 2022-05-31 | Ouvrir |
| NCT05208840 LEGATO — A Study To Determine The Effect Of Ocrelizumab On Leptomeninge… |
Ocrelizumab | SEP | Phase 4 | WITHDRAWN | En attente / non publié | Hoffmann-La Roche | Russia · City Clinical Hospital #24; Multipal Scleros… | 2023-09-15 → 2026-01-31 | Ouvrir |
| NCT05285891 AMS05 — Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis |
Ocrelizumab | SEP | Phase 4 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States · Icahn School of Medicine at Mount Sin… | 2023-02-07 → 2032-02-25 | Ouvrir |
| NCT07503340 Operetta III — A Study to Evaluate Pharmacokinetics, Safety, Tolerabili… |
Ocrelizumab Co-formulated With rH… | SEP | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | Hoffmann-La Roche | Non communiqué | 2026-10-30 → 2031-08-01 | Ouvrir |